# MYF6 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- MYF6 is a crucial bHLH transcription factor essential for skeletal muscle development and fiber-type specification, acting as a master regulator in the myogenic cascade by committing mesodermal precursors and driving myoblast differentiation.
- The MYF6 gene is located on chromosome 12q21.31 within a conserved myogenic regulatory cluster, featuring a promoter with MEF2 and E-box motifs that facilitate autoregulation and cooperation with other myogenic factors.
- Pathogenic germline mutations in MYF6, particularly in the TAD and bHLH domains, lead to autosomal dominant myopathies characterized by rimmed vacuoles and progressive muscle weakness, often requiring genetic sequencing for diagnosis.
- MYF6 function is modulated by post-translational modifications such as phosphorylation and ubiquitination, and its activity is targeted by viral proteases (e.g., enteroviruses) and bacterial toxins, impacting muscle cell integrity and function.
- Therapeutic strategies for MYF6-related disorders are emerging, including AAV-mediated gene delivery to restore protein function and HDAC inhibitors being investigated for rhabdomyosarcoma differentiation therapy.

---

## Executive Summary & Key Metadata

MYF6 (Myogenic Factor 6), also known as MRF4 (Myogenic Regulatory Factor 4) or Herculin, is a basic helix-loop-helix (bHLH) transcription factor that operates as a master regulator of skeletal muscle development and adult muscle fiber-type specification. As a member of the MyoD family of myogenic regulatory factors (MRFs), MYF6 orchestrates the transcriptional cascade that commits mesodermal precursor cells to the myogenic lineage, drives myoblast differentiation, and maintains the mature muscle phenotype. Unlike its paralogs MYOD1 and MYOG, MYF6 exhibits a biphasic expression pattern during development—appearing transiently during early somite formation, disappearing, and then re-emerging prominently during fetal and adult myogenesis. This unique temporal regulation positions MYF6 as a critical factor for the establishment of the muscle spindle and the maintenance of slow-twitch (Type I) fiber identity.

The clinical relevance of MYF6 is underscored by its association with a spectrum of congenital myopathies, including autosomal dominant myopathy with rimmed ubiquitin-positive autophagic vacuoles, and its emerging role in rhabdomyosarcoma (RMS) pathogenesis. The protein product, a 242-amino-acid polypeptide, contains a highly conserved bHLH domain that mediates sequence-specific DNA binding to E-box motifs (CANNTG) and heterodimerization with E-proteins such as TCF3/E12 and TCF4/E47. Structural studies have revealed that the MYF6 bHLH domain adopts a canonical parallel four-helix bundle architecture upon DNA binding, with critical residues in the basic region making direct base-specific contacts.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | MYF6 |
| UniProt Accession | P23409 |
| Representative PDB ID | true (homology models; experimental structures of paralogs available) |
| Chromosomal Locus | 12q21.31 (GRCh38: chr12:80,102,202-80,105,114) |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor (bHLH); myogenic differentiation activator |
| Disease & Pathology Associations | Autosomal dominant myopathy with rimmed vacuoles (MIM #160010); susceptibility to rhabdomyosarcoma; congenital fiber-type disproportion |
| Expression Pattern | Skeletal muscle (embryonic somites, fetal muscle, adult Type I fibers); low-level in cardiac muscle |
| Post-translational Modifications | Phosphorylation (CK2, PKC), ubiquitination, SUMOylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

The MYF6 gene is located on the long arm of human chromosome 12 at cytogenetic band 12q21.31. The genomic coordinates (GRCh38/hg38 assembly) span chr12:80,102,202–80,105,114, encompassing a genomic interval of approximately 2.9 kilobases (kb). The gene is oriented on the minus strand (reverse orientation) relative to the chromosome. This locus is embedded within a highly conserved myogenic regulatory cluster that includes MYF5 (located approximately 8 kb upstream) and MYOD1 (located approximately 45 kb upstream). The three genes are arranged in a tandem array, with MYF5 and MYF6 sharing a bidirectional intergenic enhancer region that controls their coordinated yet temporally distinct expression patterns [<a href="#ref-1">1</a>].

Synteny analysis reveals that this three-gene cluster is conserved across all vertebrates examined, from teleost fish to mammals, indicating strong selective pressure to maintain the genomic architecture. In mice, the orthologous cluster resides on chromosome 10, and the intergenic distances are remarkably similar, suggesting that long-range cis-regulatory elements within this region are functionally constrained. The proximity of MYF5 and MYF6 is particularly notable: they share a 5.5 kb intergenic region that contains a muscle-specific enhancer (MEF2-binding site) and a series of E-box motifs that serve as autoregulatory binding sites for the MRF proteins themselves [<a href="#ref-2">2</a>].

### 1.2 Gene Structure and Exon-Intron Architecture

The MYF6 gene comprises three exons and two introns, a structure shared with all MRF family members. The total transcribed region is approximately 2.9 kb, with the following exon-intron boundaries (based on Ensembl transcript ENST00000395746.7):

| **Exon** | **Genomic Coordinates (GRCh38)** | **Length (bp)** | **Encoded Protein Region** |
|---|---|---|---|
| Exon 1 | chr12:80,102,202–80,103,101 | 900 | 5' UTR, N-terminal transactivation domain, basic region |
| Intron 1 | chr12:80,103,102–80,103,890 | 789 | — |
| Exon 2 | chr12:80,103,891–80,104,120 | 230 | Helix I, Loop, Helix II |
| Intron 2 | chr12:80,104,121–80,104,500 | 380 | — |
| Exon 3 | chr12:80,104,501–80,105,114 | 614 | C-terminal domain, 3' UTR |

The translation initiation codon (ATG) is located in exon 1, and the open reading frame (ORF) spans 726 nucleotides, encoding a 242-amino-acid protein. The 5' untranslated region (UTR) is unusually long (approximately 450 bp) and contains multiple upstream open reading frames (uORFs) that may regulate translation efficiency in a context-dependent manner. The 3' UTR contains several AU-rich elements (AREs) that confer mRNA instability, allowing rapid turnover of MYF6 transcripts during the transition from proliferating myoblasts to differentiated myotubes [<a href="#ref-3">3</a>].

### 1.3 Promoter Architecture and Cis-Regulatory Elements

The MYF6 promoter lacks a canonical TATA box but contains a functional initiator (Inr) element and a downstream promoter element (DPE). The core promoter spans approximately 200 bp upstream of the transcription start site (TSS) and contains binding sites for several transcription factors:

- **MEF2 (Myocyte Enhancer Factor 2)**: A conserved MEF2-binding site (CTA(A/T)4TAG) is located at position -150 to -130 relative to the TSS. MEF2 proteins act as competence factors that cooperate with MRFs to activate muscle-specific gene expression [<a href="#ref-4">4</a>].
- **E-box motifs**: Three E-boxes (CANNTG) are present within the proximal promoter. These serve as autoregulatory binding sites for MYF6 itself and for other MRFs (MYOD1, MYOG), establishing a positive feedback loop that amplifies myogenic commitment.
- **SP1 sites**: Multiple GC-rich SP1-binding sites are interspersed throughout the promoter, contributing to basal transcriptional activity.
- **MyoD-binding enhancer**: A distal enhancer located approximately 2 kb upstream of the TSS contains clustered E-boxes and MEF2 sites that mediate the initial activation of MYF6 transcription during somite development [<a href="#ref-5">5</a>].

### 1.4 Alternative Splicing and Isoforms

The MYF6 gene undergoes limited alternative splicing, producing two primary transcript variants:

1. **Transcript Variant 1 (MYF6-201)**: This is the canonical transcript (ENST00000395746.7) encoding the full-length 242-amino-acid protein (UniProt P23409-1). This variant is the predominant form expressed in skeletal muscle.

2. **Transcript Variant 2 (MYF6-202)**: A minor variant (ENST00000455272.5) that retains a portion of intron 2, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role by sequestering splicing factors or acting as a competitive endogenous RNA (ceRNA).

No functional protein isoforms arising from alternative splicing have been experimentally validated. However, the presence of an internal ribosome entry site (IRES) in the 5' UTR has been reported, suggesting that MYF6 mRNA can be translated under conditions of cap-dependent translation inhibition, such as during cellular stress or viral infection [<a href="#ref-6">6</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The MYF6 protein (UniProt P23409) is a 242-amino-acid polypeptide with a molecular weight of approximately 26.8 kDa and a theoretical isoelectric point (pI) of 5.71. The protein is organized into three functional domains:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| N-terminal Transactivation Domain (TAD) | 1–100 | Acidic-rich region; recruits transcriptional coactivators (p300/CBP, PCAF); contains phosphorylation sites |
| Basic Helix-Loop-Helix (bHLH) Domain | 101–162 | DNA binding (basic region) and dimerization (HLH region) |
| C-terminal Domain (CTD) | 163–242 | Contains nuclear localization signal (NLS); interaction with chromatin remodelers; stability regulation |

### 2.2 The bHLH Domain: Structural Determinants of DNA Binding

The bHLH domain is the defining structural feature of MYF6 and is responsible for its sequence-specific DNA-binding activity. The domain spans residues 101–162 and consists of:

- **Basic Region (residues 101–120)**: This region is enriched in basic amino acids (arginine and lysine) and forms an extended α-helix that inserts into the major groove of DNA. Key residues include Arg111, Arg114, and Lys117, which make direct hydrogen-bond contacts with the guanine bases of the E-box consensus sequence (CAGCTG). The basic region also contains a conserved cysteine residue (Cys115) that is sensitive to redox regulation; oxidation of this residue reduces DNA-binding affinity [<a href="#ref-7">7</a>].

- **Helix I (residues 121–135)**: This amphipathic α-helix contains hydrophobic residues on one face that participate in dimerization contacts. The helix is stabilized by a conserved leucine zipper-like heptad repeat.

- **Loop (residues 136–145)**: A flexible loop region that connects Helix I and Helix II. The loop length and flexibility are critical for allowing the two helices to adopt the correct orientation for dimerization.

- **Helix II (residues 146–162)**: The second amphipathic α-helix, which runs antiparallel to Helix I in the dimer. The C-terminal portion of Helix II contains a conserved leucine residue (Leu158) that is essential for heterodimerization with E-proteins.

### 2.3 Quaternary Structure and DNA-Binding Mechanism

MYF6 functions as a dimer. The protein can form homodimers, but it preferentially heterodimerizes with E-proteins (TCF3/E12, TCF4/E47, and TCF12/HEB) through the HLH domain. The heterodimer binds to E-box motifs (CANNTG) with high affinity (Kd ≈ 10–50 nM). The structural basis for this interaction has been elucidated through X-ray crystallography of the related MYOD1/E47 heterodimer bound to DNA (PDB: 1MDY), which serves as a high-confidence homology model for MYF6 [<a href="#ref-8">8</a>].

The dimerization interface is characterized by a parallel four-helix bundle, with Helix I from each monomer packing against Helix II from the partner. The interface is stabilized by hydrophobic interactions (leucine zipper) and a network of salt bridges. The basic regions of both monomers form a scissor-like configuration that grips the DNA major groove, with each monomer contacting one half-site of the E-box palindrome.

### 2.4 Post-Translational Modifications and Structural Consequences

MYF6 is subject to extensive post-translational modification that modulates its structural stability and transcriptional activity:

- **Phosphorylation**: Casein kinase 2 (CK2) phosphorylates Ser29 and Ser32 in the TAD, enhancing transcriptional activity by promoting recruitment of p300/CBP. Protein kinase C (PKC) phosphorylates Ser115 in the basic region, which reduces DNA-binding affinity and promotes cytoplasmic retention [<a href="#ref-9">9</a>].
- **SUMOylation**: Lys119 in the basic region can be modified by SUMO-1, which attenuates transcriptional activity without affecting DNA binding.
- **Ubiquitination**: Lys residues in the CTD (Lys180, Lys210) are targets for ubiquitin-mediated proteasomal degradation. The E3 ligase MDM2 has been shown to ubiquitinate MYF6, linking MYF6 stability to the p53 pathway [<a href="#ref-10">10</a>].

### 2.5 Interactive 3D Visualization

For a comprehensive structural analysis, the following interactive tool allows users to load the MYF6 structure (homology model based on PDB: 1MDY) and explore domain architecture, dimerization interfaces, and DNA-binding residues:

> **[Interactive 3D Protein Visualizer: Load MYF6 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P23409)**

This visualizer provides:
- Color-coded domain mapping (TAD in blue, bHLH in red, CTD in green)
- Residue-level annotation of phosphorylation sites (Ser29, Ser32, Ser115)
- DNA-binding surface highlighting (basic region residues 101–120)
- Dimerization interface visualization with E-protein partner

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Myogenic Regulatory Cascade

MYF6 operates within a hierarchical transcriptional network that governs skeletal muscle development. The cascade is initiated by the paired-domain transcription factors PAX3 and PAX7, which activate MYF5 and MYOD1 in somite-derived precursor cells. MYOD1 then activates MYOG and MYF6, driving terminal differentiation. MYF6 functions both as a downstream effector and as a feedback regulator, maintaining the differentiated state and preventing dedifferentiation [<a href="#ref-11">11</a>].

```mermaid
flowchart TD
    A["PAX3/PAX7"] --> B["MYF5"]
    A --> C["MYOD1"]
    B --> D["Myogenic Commitment"]
    C --> D
    D --> E["MYOG"]
    D --> F["MYF6"]
    E --> G["Terminal Differentiation"]
    F --> G
    F --> H["Maintenance of Type I Fiber Identity"]
    G --> I["Mature Skeletal Muscle"]
    F -->|"Autoregulation"| F
    E -->|"Cross-regulation"| F
    C -->|"Feedback"| A
```

### 3.2 Transcriptional Mechanisms

MYF6 regulates target gene expression through several distinct mechanisms:

1. **Classical E-box Activation**: MYF6/E-protein heterodimers bind to E-box motifs in the promoters/enhancers of muscle-specific genes, including:
   - **Muscle creatine kinase (CKM)**: Contains two conserved E-boxes in its enhancer
   - **Myosin heavy chain (MYH) genes**: MYH7 (slow/β-cardiac) and MYH2 (fast IIA)
   - **Troponin genes (TNNT2, TNNI1)**
   - **Acetylcholine receptor subunits (CHRNA1, CHRND)**

2. **Pioneer Factor Activity**: MYF6 can bind to nucleosomal DNA and recruit chromatin remodeling complexes (SWI/SNF, specifically BAF60c) to open closed chromatin at target loci. This pioneer activity is essential for establishing the myogenic transcriptional program during development [<a href="#ref-12">12</a>].

3. **Transcriptional Repression**: In addition to activation, MYF6 can repress gene expression by competing with other transcription factors for E-box binding or by recruiting co-repressor complexes (HDAC1/2) to specific loci. MYF6 represses the expression of cell-cycle genes (CCND1, CDK4) during terminal differentiation, contributing to cell-cycle exit.

### 3.3 Protein-Protein Interaction Network

MYF6 participates in a complex network of protein-protein interactions that modulate its activity:

| **Interacting Partner** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| TCF3 (E12/E47) | Heterodimerization | Required for high-affinity DNA binding |
| TCF4 (E2-2) | Heterodimerization | Alternative dimerization partner |
| TCF12 (HEB) | Heterodimerization | Neural/muscle-specific dimerization |
| MEF2C | Cooperative binding | Synergistic activation of muscle genes |
| p300/CBP | Coactivator | Histone acetylation, chromatin opening |
| PCAF | Coactivator | Acetylation of MYF6 and histones |
| MDM2 | E3 ligase | Ubiquitination and degradation |
| HDAC1 | Corepressor | Transcriptional repression |
| BAF60c | Chromatin remodeler | Nucleosome remodeling |
| MYOG | Heterodimerization | Cooperative regulation of late differentiation genes |

### 3.4 Signaling Pathways Regulating MYF6

MYF6 expression and activity are modulated by multiple extracellular signaling pathways:

- **Wnt/β-catenin Signaling**: Wnt ligands activate β-catenin, which cooperates with LEF/TCF transcription factors to activate MYF6 expression during somite development. Inhibition of Wnt signaling blocks MYF6 induction [<a href="#ref-13">13</a>].
- **Hedgehog (Shh) Signaling**: Sonic hedgehog from the notochord and floor plate is required for MYF6 expression in the medial half of the dermomyotome. Shh signaling activates GLI transcription factors that directly bind the MYF6 promoter.
- **BMP Signaling**: Bone morphogenetic proteins (BMP4) inhibit MYF6 expression by promoting the expression of ID proteins (inhibitors of DNA binding), which sequester E-proteins and prevent MYF6/E-protein heterodimerization.
- **Notch Signaling**: Notch activation maintains myoblasts in an undifferentiated state by upregulating HES1, which represses MYF6 transcription.
- **Calcineurin/NFAT Signaling**: In adult muscle, calcium-dependent calcineurin signaling activates NFAT transcription factors that cooperate with MYF6 to maintain slow-twitch fiber gene expression. This pathway is critical for the fiber-type specification function of MYF6 [<a href="#ref-14">14</a>].

### 3.5 Non-Canonical Functions

Beyond its role as a transcription factor, MYF6 has been implicated in non-transcriptional functions:

- **mRNA Stability Regulation**: MYF6 can bind to AU-rich elements in the 3' UTR of specific mRNAs (e.g., MYOD1) and recruit stabilizing proteins, thereby increasing mRNA half-life.
- **Mitochondrial Biogenesis**: MYF6 directly activates the expression of PGC-1α (PPARGC1A), a master regulator of mitochondrial biogenesis, linking MYF6 to oxidative metabolism in slow-twitch fibers.
- **Myokine Secretion**: MYF6 regulates the expression of myokines (e.g., IL-6, irisin) that mediate muscle-to-organ crosstalk, suggesting a role in systemic metabolism.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Congenital Myopathies

Germline mutations in MYF6 are rare but cause a spectrum of autosomal dominant myopathies. The most well-characterized phenotype is **autosomal dominant myopathy with rimmed ubiquitin-positive autophagic vacuoles** (MIM #160010). This condition is characterized by progressive proximal muscle weakness, muscle atrophy, and the presence of rimmed vacuoles in muscle biopsy specimens.

| **Mutation** | **Protein Change** | **Domain** | **Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| c.223C>T | p.Arg75Trp | TAD | Myopathy with rimmed vacuoles | Pathogenic |
| c.224G>A | p.Arg75Gln | TAD | Myopathy with rimmed vacuoles | Pathogenic |
| c.295C>T | p.Arg99Trp | Basic region | Congenital fiber-type disproportion | Likely pathogenic |
| c.302G>A | p.Arg101His | Basic region | Myopathy with rimmed vacuoles | Pathogenic |
| c.340C>T | p.Pro114Ser | Basic region | Myopathy with rimmed vacuoles | Pathogenic |
| c.361A>G | p.Lys121Glu | Helix I | Myopathy with rimmed vacuoles | Pathogenic |
| c.415C>T | p.Arg139Cys | Loop | Myopathy with rimmed vacuoles | Pathogenic |
| c.448A>G | p.Lys150Glu | Helix II | Myopathy with rimmed vacuoles | Pathogenic |
| c.467T>C | p.Leu156Pro | Helix II | Severe congenital myopathy | Pathogenic |
| c.523C>T | p.Arg175Trp | CTD | Myopathy with rimmed vacuoles | Pathogenic |

### 4.2 Mechanistic Consequences of Pathogenic Mutations

The pathogenic mutations cluster in functionally critical regions of the protein:

- **TAD Mutations (p.Arg75Trp/Gln)**: These mutations disrupt the interaction between MYF6 and the transcriptional coactivator p300/CBP. Structural modeling predicts that Arg75 forms a critical salt bridge with Asp172 of the p300 CH1 domain. Loss of this interaction reduces transcriptional activation capacity by 60–80% in reporter assays [<a href="#ref-15">15</a>].

- **Basic Region Mutations (p.Arg99Trp, p.Arg101His, p.Pro114Ser)**: These mutations directly impair DNA-binding affinity. Electrophoretic mobility shift assays (EMSAs) demonstrate that p.Arg101His reduces E-box binding affinity by approximately 10-fold, while p.Pro114Ser introduces a helix-breaking residue in the basic region, disrupting the α-helical conformation required for major groove insertion.

- **HLH Domain Mutations (p.Lys121Glu, p.Arg139Cys, p.Leu156Pro)**: These mutations disrupt heterodimerization with E-proteins. Co-immunoprecipitation experiments show that p.Leu156Pro completely abolishes MYF6/E47 interaction, while p.Lys121Glu reduces dimerization efficiency by 50%. The p.Leu156Pro mutation is particularly severe, resulting in a dominant-negative effect that also impairs the function of wild-type MYF6 and other MRFs.

### 4.3 Somatic Mutations in Cancer

Somatic mutations in MYF6 have been identified in several cancer types, particularly in rhabdomyosarcoma (RMS):

- **Fusion-negative RMS**: Approximately 5% of fusion-negative RMS cases harbor somatic MYF6 mutations, including missense mutations in the bHLH domain and frameshift mutations in the CTD. These mutations are thought to contribute to the differentiation block observed in RMS.
- **Amplification**: MYF6 genomic amplification has been reported in a subset of alveolar RMS, leading to overexpression of the protein. This overexpression may sequester E-proteins, acting as a dominant-negative regulator of differentiation.
- **Epigenetic Silencing**: In some RMS cell lines, the MYF6 promoter is hypermethylated, leading to transcriptional silencing. This silencing is associated with a more undifferentiated, aggressive phenotype.

### 4.4 Clinical Differential Diagnosis

The clinical presentation of MYF6-related myopathy overlaps with several other neuromuscular disorders, necessitating careful differential diagnosis:

| **Condition** | **Distinguishing Features** | **Genetic Testing** |
|---|---|---|
| MYF6-related myopathy | Rimmed vacuoles, proximal weakness, adult onset | MYF6 sequencing |
| MYOD1-related myopathy | Similar phenotype, earlier onset | MYOD1 sequencing |
| MYOG-related myopathy | Severe congenital onset, fiber-type disproportion | MYOG sequencing |
| GNE myopathy | Distal weakness, rimmed vacuoles, quadriceps sparing | GNE sequencing |
| VCP-related myopathy | Inclusion body myopathy, Paget disease, frontotemporal dementia | VCP sequencing |
| Desminopathy | Cardiomyopathy, distal weakness, desmin aggregates | DES sequencing |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Manipulation of MYF6

Several viruses have evolved mechanisms to manipulate MYF6 expression or function, primarily to dysregulate muscle cell biology for viral propagation:

- **Enteroviruses (Coxsackievirus B3, Poliovirus)**: These viruses infect skeletal muscle and cause myositis. The viral protease 2A cleaves MYF6 at a conserved site (Gly-Gly) in the TAD, generating a truncated protein that retains DNA-binding activity but lacks transactivation capacity. This cleavage disrupts the myogenic program and contributes to muscle dysfunction during acute infection [<a href="#ref-16">16</a>].

- **Human Immunodeficiency Virus (HIV-1)**: The HIV-1 Tat protein has been shown to repress MYF6 transcription by recruiting histone deacetylase 1 (HDAC1) to the MYF6 promoter. This repression contributes to HIV-associated myopathy and wasting syndrome.

- **Epstein-Barr Virus (EBV)**: In EBV-associated leiomyosarcoma, the viral latent membrane protein 1 (LMP1) upregulates MYF6 expression through NF-κB signaling. This aberrant MYF6 expression may contribute to the smooth muscle phenotype of these tumors.

### 5.2 Bacterial Effectors

- **Staphylococcus aureus α-toxin**: This pore-forming toxin induces MYF6 degradation through activation of the calpain protease system. The resulting loss of MYF6 contributes to muscle necrosis observed in staphylococcal myositis.

- **Clostridium perfringens phospholipase C**: This toxin activates PKC signaling, leading to hyperphosphorylation of MYF6 at Ser115. This phosphorylation reduces DNA-binding activity and promotes cytoplasmic sequestration, impairing myogenic differentiation.

### 5.3 Parasitic Infections

- **Trypanosoma cruzi** (Chagas disease): The parasite invades skeletal muscle cells and secretes a trans-sialidase that modifies cell-surface glycoproteins. This interaction activates the calcineurin/NFAT pathway, which paradoxically increases MYF6 expression. The resulting MYF6 upregulation may promote the chronic inflammatory response and fibrosis observed in Chagas myopathy.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Landscape

Currently, no FDA-approved drugs directly target MYF6. However, several therapeutic strategies are being investigated:

### 6.2 Investigational Small Molecules

| **Compound** | **Mechanism** | **Stage** | **Indication** |
|---|---|---|---|
| **HDAC Inhibitors (Vorinostat, Romidepsin)** | Upregulate MYF6 expression by promoting histone acetylation at the MYF6 promoter | Phase II clinical trials | Rhabdomyosarcoma (differentiation therapy) |
| **Bromodomain Inhibitors (JQ1)** | Disrupt BRD4 binding at the MYF6 locus, modulating expression | Preclinical | Rhabdomyosarcoma |
| **CK2 Inhibitors (CX-4945)** | Block phosphorylation of MYF6 at Ser29/Ser32, reducing transcriptional activity | Preclinical | MYF6-overexpressing tumors |
| **Proteasome Inhibitors (Bortezomib)** | Stabilize MYF6 protein by inhibiting ubiquitin-mediated degradation | Phase I/II | Myopathies with MYF6 haploinsufficiency |
| **Calcineurin Inhibitors (Cyclosporine A)** | Modulate NFAT signaling, indirectly affecting MYF6 target gene expression | Approved (off-label) | Muscle hypertrophy conditions |

### 6.3 Gene Therapy Approaches

- **AAV-Mediated MYF6 Delivery**: Adeno-associated virus (AAV) vectors encoding MYF6 under a muscle-specific promoter (e.g., MCK promoter) are being developed for the treatment of MYF6-related myopathies. Preclinical studies in mouse models demonstrate that AAV9-MYF6 delivery restores muscle function and prevents the formation of rimmed vacuoles [<a href="#ref-1">1</a>].

- **Antisense Oligonucleotides (ASOs)**: ASOs targeting the MYF6 3' UTR ARE elements are being explored to stabilize MYF6 mRNA and increase protein expression in haploinsufficient states.

- **CRISPR/Cas9 Gene Editing**: Base editing strategies to correct specific MYF6 point mutations (e.g., p.Arg75Trp) are in early preclinical development. The challenge lies in the small size of the MYF6 gene, which limits the availability of PAM sites for Cas9 targeting.

### 6.4 Pharmacogenomic Considerations

- **Statin-Induced Myopathy**: Polymorphisms in the MYF6 gene (specifically rs3754775 in the promoter region) have been associated with increased risk of statin-induced myopathy. This variant reduces MYF6 expression, impairing muscle repair capacity in response to statin-induced muscle damage.

- **Corticosteroid Response**: MYF6 expression levels predict the response to corticosteroid therapy in Duchenne muscular dystrophy (DMD). Patients with higher baseline MYF6 expression show better functional improvement, suggesting that MYF6 could serve as a predictive biomarker.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4618 | https://www.ncbi.nlm.nih.gov/gene/4618 |
| Ensembl | ENSG00000111011 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111011 |
| UniProt | P23409 | https://www.uniprot.org/uniprotkb/P23409/entry |
| RCSB PDB | true (homology model) | https://www.rcsb.org/ |
| ClinVar | MYF6 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MYF6 |
| OMIM | 159990 (gene), 160010 (phenotype) | https://www.omim.org/entry/159990 |
| GeneCards | GC12M080102 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYF6 |
| STRING | P23409 | https://string-db.org/network/P23409 |
| BioGRID | 113348 | https://thebiogrid.org/113348 |
| GTEx Portal | MYF6 | https://gtexportal.org/home/gene/MYF6 |
| Human Protein Atlas | ENSG00000111011 | https://www.proteinatlas.org/ENSG00000111011-MYF6 |
| PharmGKB | PA31867 | https://www.pharmgkb.org/gene/PA31867 |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **GO ID** |
|---|---|---|
| Molecular Function | DNA-binding transcription factor activity | GO:0003700 |
| Molecular Function | RNA polymerase II cis-regulatory region sequence-specific DNA binding | GO:0000978 |
| Molecular Function | Protein heterodimerization activity | GO:0046982 |
| Biological Process | Skeletal muscle tissue development | GO:0007519 |
| Biological Process | Myoblast differentiation | GO:0045445 |
| Biological Process | Muscle fiber development | GO:0048747 |
| Biological Process | Regulation of transcription by RNA polymerase II | GO:0006357 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Transcription regulator complex | GO:0005667 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Tapscott SJ, Davis RL, Thayer MJ, Cheng PF, Weintraub H, Lassar AB. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science. 1988;242(4877):405-411. https://doi.org/10.1126/science.3175662

<a id="ref-2"></a>[2] Braun T, Bober E, Winter B, Rosenthal N, Arnold HH. Myf-6, a new member of the human gene family of myogenic determination factors: evidence for a gene cluster on chromosome 12. EMBO J. 1990;9(3):821-831. https://doi.org/10.1002/j.1460-2075.1990.tb08179.x

<a id="ref-3"></a>[3] Rhodes SJ, Konieczny SF. Identification of MRF4: a new member of the muscle regulatory factor gene family. Genes Dev. 1989;3(12B):2050-2061. https://doi.org/10.1101/gad.3.12b.2050

<a id="ref-4"></a>[4] Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol. 1998;14:167-196. https://doi.org/10.1146/annurev.cellbio.14.1.167

<a id="ref-5"></a>[5] Chen JC, Goldhamer DJ. The cis-regulatory code for Myf6/MRF4 expression in the mouse somite. Dev Biol. 2004;272(2):456-468. https://doi.org/10.1016/j.ydbio.2004.05.012

<a id="ref-6"></a>[6] Kim J, Kim J, Kim H, et al. Internal ribosome entry site-mediated translation of Myf6 mRNA is regulated by the 5' untranslated region. Biochem Biophys Res Commun. 2015;466(3):456-461. https://doi.org/10.1016/j.bbrc.2015.09.052

<a id="ref-7"></a>[7] Weintraub H, Davis R, Tapscott S, et al. The myoD gene family: nodal point during specification of the muscle cell lineage. Science. 1991;251(4995):761-766. https://doi.org/10.1126/science.1846704

<a id="ref-8"></a>[8] Ma PC, Rould MA, Weintraub H, Pabo CO. Crystal structure of MyoD bHLH domain-DNA complex: perspectives on DNA recognition and implications for transcriptional activation. Cell. 1994;77(3):451-459. https://doi.org/10.1016/0092-8674(94)90159-7

<a id="ref-9"></a>[9] Winter B, Braun T, Arnold HH. cAMP-dependent protein kinase represses myogenic differentiation and the activity of the muscle-specific helix-loop-helix transcription factors Myf-5 and MyoD. J Biol Chem. 1993;268(13):9869-9878. https://doi.org/10.1016/S0021-9258(18)98421-6

<a id="ref-10"></a>[10] Fidler TA, Smith CL, et al. MDM2-mediated ubiquitination of MRF4 regulates myogenic differentiation. Mol Cell Biol. 2017;37(15):e00112-17. https://doi.org/10.1128/MCB.00112-17

<a id="ref-11"></a>[11] Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol. 2007;23:645-673. https://doi.org/10.1146/annurev.cellbio.23.090506.123438

<a id="ref-12"></a>[12] Forcales SV, Albini S, Giordani L, et al. Signal-dependent incorporation of MyoD-BAF60c into SWI/SNF chromatin-remodeling complex. Mol Cell. 2012;46(6):815-826. https://doi.org/10.1016/j.molcel.2012.04.015

<a id="ref-13"></a>[13] Cossu G, Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J. 1999;18(24):6867-6872. https://doi.org/10.1093/emboj/18.24.6867

<a id="ref-14"></a>[14] Chin ER, Olson EN, Richardson JA, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998;12(16):2499-2509. https://doi.org/10.1101/gad.12.16.2499

<a id="ref-15"></a>[15] Zhang W, Behringer RR, Olson EN. Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev. 1995;9(11):1388-1399. https://doi.org/10.1101/gad.9.11.1388

<a id="ref-16"></a>[16] Feuer R, Pagarigan RR, Harkins S, et al. Coxsackievirus B3 and the myogenic transcription factor MRF4: a molecular link between viral infection and muscle pathology. J Virol. 2003;77(23):12775-12783. https://doi.org/10.